Vascular Biogenics Ltd. (VBLT) Upgraded by Zacks Investment Research to Buy
Zacks Investment Research upgraded shares of Vascular Biogenics Ltd. (NASDAQ:VBLT) from a hold rating to a buy rating in a research report released on Tuesday. They currently have $5.50 target price on the biopharmaceutical company’s stock.
According to Zacks, “Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel. “
Other research analysts have also recently issued reports about the stock. HC Wainwright reaffirmed a buy rating on shares of Vascular Biogenics in a report on Monday. Roth Capital reaffirmed a buy rating and set a $17.00 target price on shares of Vascular Biogenics in a report on Tuesday, August 16th. Six research analysts have rated the stock with a buy rating, Vascular Biogenics currently has an average rating of Buy and a consensus price target of $11.10.
Vascular Biogenics (NASDAQ:VBLT) traded down 0.51% on Tuesday, reaching $4.90. 74,876 shares of the company traded hands. The stock has a 50-day moving average of $5.05 and a 200 day moving average of $4.34. Vascular Biogenics has a 52-week low of $2.76 and a 52-week high of $7.58. The company’s market capitalization is $115.65 million.
Vascular Biogenics (NASDAQ:VBLT) last released its quarterly earnings results on Thursday, November 10th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.03. On average, equities analysts forecast that Vascular Biogenics will post ($0.60) EPS for the current year.
Hedge funds have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Vascular Biogenics during the second quarter worth $1,844,000. Macquarie Group Ltd. bought a new stake in shares of Vascular Biogenics during the second quarter worth $1,521,000. First Eagle Investment Management LLC raised its stake in shares of Vascular Biogenics by 371.1% in the second quarter. First Eagle Investment Management LLC now owns 923,239 shares of the biopharmaceutical company’s stock worth $4,256,000 after buying an additional 727,273 shares in the last quarter. Turner Investments L.P. bought a new stake in shares of Vascular Biogenics during the second quarter worth $1,007,000. Finally, Knoll Capital Management LP bought a new stake in shares of Vascular Biogenics during the third quarter worth $4,406,000. Hedge funds and other institutional investors own 14.41% of the company’s stock.
About Vascular Biogenics
Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company’s program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels.
Receive News & Stock Ratings for Vascular Biogenics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vascular Biogenics Ltd. and related stocks with our FREE daily email newsletter.